Biological

R-AD26-S (recombinant adenovirus type 26 carrying THE gene FOR severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike glycoprotein) clinical trials

Also written rAd26-S.

studies test it: 3
open now: 0
in phase 3: 0
first study started: 2021

How studies write it

Studies that test it under each name

Other names

rAd26-S: 3

By phase

A phase 1/2 study counts in both.

Phase 1: 2
Phase 2: 3

What it is tested for

Each study’s main condition, where its own words name it.

COVID-19: 3

Who runs them

Industry 3 · Other 0

R-Pharm (3)

Often tested with

Tested in the same studies.

ChAdOx1 nCoV-19 (3)

Studies

Open first, then newest update. How each study uses R-AD26-S (recombinant adenovirus type 26 carrying THE gene FOR severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike glycoprotein) is read from its arms, and is right about nine times in ten.

Testing it · 3

Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)CompletedPhase 1/2R-PharmNCT04760730Written as rAd26-S
Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 PreventionCompletedPhase 2R-PharmNCT04686773Written as rAd26-S
Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19CompletedPhase 1/2R-PharmNCT04684446Written as rAd26-S